Mar 14, 2023 / 05:35PM GMT
Matthew Stephan Miksic - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everybody. Thanks for joining us today. My name is Matt Miksic. I cover medical devices here at Barclays in the U.S.
I'm very pleased to have with us today the team from Henry Schein, Ron South, SVP and CFO; and Graham Stanley, Head of IR. So thanks, guys, for coming, so much.
Questions and Answers:
Matthew Stephan Miksic - Barclays Bank PLC, Research Division - Research AnalystSo maybe I thought we might start with -- I want to take a break here and hear for the questions from the audience if there are any, maybe about 5 or 10 minutes in, but I thought we'd start with just a long-term plan. And going through the slides and taking a look at the sort of market growth and the way that you framed it out. You talked about 6% to 8% organic growth on the top line, 8% to 11% EPS growth.
But the -- it struck me that looking at your markets, you have dental growing in like the 2% to 4% range, but then dental -- and specialty is 5% to 8%; technology,
Trustpilot
